Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2+ Metastatic Breast Cancer (MBC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01495247
What this trial is testing

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Inoperable Locally Advanced Breast CancerMetastatic Breast Cancer (MBC)
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Ended earlyNCT01512199
What this trial is testing

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Daiichi Sankyo 29
Not applicableStudy completedNCT05054166
What this trial is testing

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Who this might be right for
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Zhejiang Cancer Hospital 14
Not applicableStudy completedNCT06961331
What this trial is testing

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Who this might be right for
Metastatic HER2+ Advanced Breast Cancer
Pfizer 86
Early research (Phase 1)Study completedNCT02684032
What this trial is testing

Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Celcuity Inc 141
Testing effectiveness (Phase 2)Study completedNCT01138046
What this trial is testing

Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 12
Testing effectiveness (Phase 2)Study completedNCT01446159
What this trial is testing

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Who this might be right for
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
MedImmune LLC 188
Testing effectiveness (Phase 2)UnknownNCT03910712
What this trial is testing

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Who this might be right for
Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast+3 more
Peking Union Medical College Hospital 250
Not applicableStudy completedNCT01160094
What this trial is testing

Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

Who this might be right for
Cancer
Novartis 288
Testing effectiveness (Phase 2)Study completedNCT03213041
What this trial is testing

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
Northwestern University 12
Testing effectiveness (Phase 2)Ended earlyNCT02202746
What this trial is testing

Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerMBC+5 more
Clovis Oncology, Inc. 178
Not applicableStudy completedNCT04480814
What this trial is testing

Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC

Who this might be right for
Breast Cancer
Pharmassist Ltd 30
Testing effectiveness (Phase 2)Study completedNCT03222856
What this trial is testing

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

Who this might be right for
Breast Cancer
MedSIR 44
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Testing effectiveness (Phase 2)Looking for participantsNCT07007559
What this trial is testing

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer, Metastatic
ALX Oncology Inc. 120
Early research (Phase 1)Study completedNCT03238196
What this trial is testing

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center 35
Testing effectiveness (Phase 2)Ended earlyNCT03952325
What this trial is testing

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 294
Testing effectiveness (Phase 2)Study completedNCT00386685
What this trial is testing

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Sanofi 51
Testing effectiveness (Phase 2)Study completedNCT04072952
What this trial is testing

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Arvinas Estrogen Receptor, Inc. 217
Early research (Phase 1)Study completedNCT04818632
What this trial is testing

AZD9833 China PK Study

Who this might be right for
ER+, HER2-, Metastatic Breast Cancer
AstraZeneca 28
Next Page